IMM-1-104 combined with mGnP shows promising efficacy and tolerability in first-line pancreatic cancer, with a 43% ORR and 86% DCR among seven patients. IMM-1-104 demonstrated target lesion shrinkage ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

马萨诸塞州剑桥市 - 市值5,931万美元的临床阶段肿瘤公司Immuneering Corporation (NASDAQ: IMRX )与Regeneron制药公司达成临床供应协议，评估其主要产品候选药物IMM-1-104与Regeneron的抗PD-1疗法Libtayo（cemiplimab）的联合用药潜力。根据 InvestingPro ...

“We are thrilled to report two more responses in our Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer,” said Ben Zeskind, Ph.D., CEO of ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

(RTTNews) - Immuneering Corporation (IMRX), a Massachusetts-based biopharmaceutical company Monday announced a positive update from its Phase 2a study of IMM-1-104 combined with modified ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial - - Data presented at AACR 2023 supports ...